21 天前 - … review racial demographics for phase III clinical trials. These trials evaluated systemic
anti-cancer … Studies were excluded if they did not include racial demographic information. …

21 天前 - … Background: T-DXd is a targeted therapy shown to improve outcomes in patients
with metastatic breast cancer (MBC) who progressed on prior HER2 targeted therapies, or in …

21 天前 - … factors influencing the duration from cancer diagnosis to treatment among adult
patients greater than 18 years old diagnosed with lung cancers. Shorter TTI intervals were …

21 天前 - … of breast cancer patients become candidates for breast … of surgical decision-making
in breast cancer, there is little … chart review was conducted on breast cancer patients at …

21 天前 - … we reviewed patient characteristics, access to care, and uptake of screening
mammogram (SMMG) prior to a breast cancer … Race/ethnicity, insurance status, and positive family …

21 天前 - … is an integral part of breast cancer survivorship care. … of racial minorities in supportive
care breast cancer (BC) clinical trials (CTs). Methods: We conducted a systematic review …

21 天前 - … chemotherapy were breast cancer (… difference in race, age at cancer diagnosis,
surgery rate, treatment with hormone therapy, or secondary malignancy between the two groups …

21 天前 - … Many biological and societal factors can affect breast cancer mortality. We sought to
… (GM), breast cancer subtype, and mortality based on race in a unique, young breast cancer …

21 天前 - … susceptibility to breast cancer was not associated with greater mortality. More has
to be done to determine if racial disparities occur in offering genetic testing to racial minorities …

21 天前 - … 4/6 inhibitors in women with breast cancer is different among patients at a community
… , HER2 negative metastatic or high risk breast cancer who started endocrine therapy and …